September 3, 2009 – Abbott said last week it received approval from Health Canada for the XIENCE V Everolimus-Eluting Coronary Stent System for the treatment of coronary artery disease (CAD).
September 2, 2009 – Edwards Lifesciences Corp. said this week it completed enrollment in its 1,040-patient randomized controlled investigational device exemption (IDE) study of the Edwards SAPIEN transcatheter heart valve.
September 3, 2009 – Boston Scientific Corp. said Tuesday long-term data from the Prevention of Sudden Cardiac Death II registry (PreSCD II) found that implantable cardioverter defibrillators (ICDs) were associated with a 44 percent reduction in all cause mortality when implanted in patients following myocardial infarction.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
September 3, 2009 – The OASIS study group presented initial results of the CURRENT-OASIS 7 clinical trial Sunday at the European Society of Cardiology Congress in Barcelona, which did not show a statistical difference between the high-dose and standard-dose PLAVIX regimens, but subgroups did show some improvement.
September 2, 2009 – Abbott announced Monday at the European Society of Cardiology Congress the widespread availability of its next-generation XIENCE PRIME Everolimus-Eluting Coronary Stent System for the treatment of coronary artery disease.
September 2, 2009 – Volcano Corp. said this week it entered into a nonexclusive, global resale agreement with Siemens Healthcare where Siemens will resell Volcano’s s5i IVUS/FFR systems and accessories alongside Siemens' Artis family of X-ray systems.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
September 2, 2009 – A new analysis from the JUPITER study showed CRESTOR (rosuvastatin calcium) 20 mg reduced the composite primary end point of major cardiovascular (CV) events (myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by 39 percent, compared to placebo, in elderly patients with LDL-C less than 130 mg/dL and elevat
September 1, 2009 - Evaluation of results of a multicenter study indicates that quantitative evaluation of the progression of volume of extracranial carotid vessel walls is feasible with 1.5T magnetic resonance (MR) imaging, despite limitations due to patient motion or habitus.
September 1, 2009 – Cordis Corp. said first patient has been enrolled in the CYPRESS study, which will assess clinical outcomes in a broad range of patients with coronary artery disease who take dual anti-platelet therapy after receiving a CYPHER sirolimus-eluting coronary stent. The procedure was performed by Patrick Flaherty, D.O., Arkansas Heart Hospital in Little Rock, Ark.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
September 1, 2009 – St. Jude Medical Inc. today announced European launch of the next generation version 4.0 of its Merlin.net Patient Care Network (PCN), a secure, Internet-based remote care system for patients with implanted medical devices.
September 1, 2009 – Sanofi-aventis said Sunday the investigational anti-Xa intravenous anti-coagulant otamixaban reduced by 27 to 42 percent the odds of the composite primary endpoint of death, myocardial infarction, urgent revascularization or rescue GPIIb/IIIa use in four out of the five otamixaban tested doses, versus standard UFH/eptifibatide combination in (non-ST) ACS patients suitable for
September 1, 2009 - BioClinica Inc., a clinical trial services provider, today announced that it has acquired the CardioNow unit of Agfa HealthCare to offer streamlined electronic transport solutions to facilitate the blinding, sharing, tracking and archiving of medical images for multi-center clinical trials as part of its suite of imaging services.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
September 1, 2009 – AstraZeneca last week announced results from the phase III head to head trial, PLATO (A Study of Platelet Inhibition and Patient Outcomes), which demonstrate that ticagrelor (BRILINTA) has achieved greater efficacy in the primary endpoint, reduction of cardiovascular events (CV death, MI, stroke) over clopidogrel (Plavix/Iscover ) (9.8 vs.
September 1, 2009 – Toshiba America Medical Systems Inc. will demonstrate its Next Generation Advanced Image Processing (AIP) feature, available on the Infinix-i product line at this year’s Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium.
September 1, 2009 – Echocardiography with Doppler is the method of choice for the noninvasive evaluation of prosthetic valves, according to a new guideline document in the September issue of the Journal of the American Society of Echocardiography (JASE).